Search results
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 7 days agoLibtayo Global Net Product Sales: Increased by 45%. Dupixent Global Net Product Sales: $3.1 billion, up 24%. EYLEA HD Sales: $200 million in its second full quarter on the ...
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
InvestorPlace· 6 days agoThis excellent opportunity that biotech stocks present can provide investors with potentially...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regeneron...
Lucentis: Side effects and how to manage them
Medical News Today· 7 days agoLucentis (ranibizumab) is a brand-name eye injection that’s prescribed for certain eye conditions in adults. As with other drugs, Lucentis can cause side...
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 7 days agoStrengths Robust Product Portfolio and Sales Growth: Regeneron's strength lies in its diverse and...
Baby Boomers' 14 Least Favorite Drug Brands: Ranked
247wallst.com· 2 days agoBaby boomers are currently one of the oldest demographics. For this reason, they’re also some of the most familiar with medications. But with so many...
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
Investor's Business Daily· 6 days agoRegeneron Pharmaceuticals missed on both metrics, with EPS down 5% and sales off 1% to $3.15...
Why Investors Are Eyeing Regeneron Pharmaceuticals Inc (REGN): T
Guru Focus· 7 days agoRegeneron Pharmaceuticals Inc (REGN) has recently captured the attention of investors and financial analysts alike, thanks to its solid financial performance an
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Merit Financial Group LLC
ETF DAILY NEWS· 21 hours agoMerit Financial Group LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 53.7% in the fourth quarter, according to its most recent filing with ...